Tags

Type your tag names separated by a space and hit enter

Broad band UVA: a possible reliable alternative to PUVA in the treatment of early-stage mycosis fungoides.
Photodermatol Photoimmunol Photomed. 2012 Oct; 28(5):274-7.PP

Abstract

UVA1 phototherapy was found to induce marked improvement in skin lesions of patients with stages IA and IB mycosis fungoides (MF). Broad band UVA (BB-UVA) is composed of 80.1% UVA1, with similar mechanisms of action. Our aim was to evaluate the efficacy of BB-UVA in the treatment of early-stage MF. Thirty patients with early stage MF were included. They were divided into two equal groups receiving either BB-UVA at 20 J/cm2/ session or PUVA three times/week for 40 sessions. Clinical and histopathological evaluations were performed before and after therapy in addition to immunohistochemical measurement of CD4+ cells and Bcl-2. Patients were followed up for an average duration of 36 months. Comparable clinical and histopathological improvement was noted in MF patients in both groups. Clinical improvement graded 'Excellent' was achieved in 33% of patients in the BB-UVA versus 13.3% in the psoralen and UVA (PUVA) group. Long-term follow-up indicated superiority of BB-UVA over PUVA. BB-UVA group showed a more rapid clearance rate, shorter time to achieve complete clearance, a longer disease-free interval and lower relapse rate. The use of BB-UVA in the treatment of early-stage MF is comparable or even superior to PUVA regarding efficacy and remission periods.

Authors+Show Affiliations

Department of Dermatology, Cairo University, Cairo, Egypt.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article

Language

eng

PubMed ID

22971197

Citation

El Mofty, Medhat, et al. "Broad Band UVA: a Possible Reliable Alternative to PUVA in the Treatment of Early-stage Mycosis Fungoides." Photodermatology, Photoimmunology & Photomedicine, vol. 28, no. 5, 2012, pp. 274-7.
El Mofty M, Ramadan S, Fawzy MM, et al. Broad band UVA: a possible reliable alternative to PUVA in the treatment of early-stage mycosis fungoides. Photodermatol Photoimmunol Photomed. 2012;28(5):274-7.
El Mofty, M., Ramadan, S., Fawzy, M. M., Hegazy, R. A., & Sayed, S. (2012). Broad band UVA: a possible reliable alternative to PUVA in the treatment of early-stage mycosis fungoides. Photodermatology, Photoimmunology & Photomedicine, 28(5), 274-7. https://doi.org/10.1111/j.1600-0781.2012.00690.x
El Mofty M, et al. Broad Band UVA: a Possible Reliable Alternative to PUVA in the Treatment of Early-stage Mycosis Fungoides. Photodermatol Photoimmunol Photomed. 2012;28(5):274-7. PubMed PMID: 22971197.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Broad band UVA: a possible reliable alternative to PUVA in the treatment of early-stage mycosis fungoides. AU - El Mofty,Medhat, AU - Ramadan,Shahira, AU - Fawzy,Marwa M, AU - Hegazy,Rehab A, AU - Sayed,Safinaz, PY - 2012/9/14/entrez PY - 2012/9/14/pubmed PY - 2013/2/5/medline SP - 274 EP - 7 JF - Photodermatology, photoimmunology & photomedicine JO - Photodermatol Photoimmunol Photomed VL - 28 IS - 5 N2 - UVA1 phototherapy was found to induce marked improvement in skin lesions of patients with stages IA and IB mycosis fungoides (MF). Broad band UVA (BB-UVA) is composed of 80.1% UVA1, with similar mechanisms of action. Our aim was to evaluate the efficacy of BB-UVA in the treatment of early-stage MF. Thirty patients with early stage MF were included. They were divided into two equal groups receiving either BB-UVA at 20 J/cm2/ session or PUVA three times/week for 40 sessions. Clinical and histopathological evaluations were performed before and after therapy in addition to immunohistochemical measurement of CD4+ cells and Bcl-2. Patients were followed up for an average duration of 36 months. Comparable clinical and histopathological improvement was noted in MF patients in both groups. Clinical improvement graded 'Excellent' was achieved in 33% of patients in the BB-UVA versus 13.3% in the psoralen and UVA (PUVA) group. Long-term follow-up indicated superiority of BB-UVA over PUVA. BB-UVA group showed a more rapid clearance rate, shorter time to achieve complete clearance, a longer disease-free interval and lower relapse rate. The use of BB-UVA in the treatment of early-stage MF is comparable or even superior to PUVA regarding efficacy and remission periods. SN - 1600-0781 UR - https://www.unboundmedicine.com/medline/citation/22971197/Broad_band_UVA:_a_possible_reliable_alternative_to_PUVA_in_the_treatment_of_early_stage_mycosis_fungoides_ L2 - https://doi.org/10.1111/j.1600-0781.2012.00690.x DB - PRIME DP - Unbound Medicine ER -